Health Economics›Extranodal NK- and T-cell lymphoma nasal type›Relapsed or refractory

Relapsed or refractory

Extranodal NK- and T-cell lymphoma nasal type · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
SMILE N/A - secondary systemic drug	—	R 3 002	28d	—	—	—	—	—
L-Asparaginase, Vincristine, Prednisolone Variant #02	—	R 933	28d	—	—	—	—	—
L-Asparaginase, Vincristine, Dexamethasone Variant #02	—	R 346	28d	—	—	—	—	—

3 of 3 regimens shown